Navigation Links
Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
Date:4/7/2010

Sullivan played a vital role in Merrimack's acquisition of Hermes Biosciences and partnership with sanofi-aventis

Cambridge, MA (PRWEB) April 7, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the discovery and development of novel treatments for cancer and inflammation, today announced that William Sullivan has been promoted to Vice President of Finance.

“Bill has led Merrimack’s finance and accounting efforts and played a vital role in both our acquisition of Hermes Biosciences and the completion of our partnership with sanofi-aventis,” said Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals. “His past experience coupled with the work he has done at Merrimack gives our leadership team and Board of Directors full confidence that Bill is the right choice to successfully direct the Company’s financial strategy.”

In his new position, Sullivan, will continue to lead Merrimack’s finance department to ensure the Company is prepared for growth and future financings. In addition to his previous role, Sullivan now has full responsibility for the Company’s daily financial and legal operations.

Bill Sullivan brings broad experience to the role. He has established and managed finance departments and worked in public and private corporate accounting. He holds a Bachelor’s degree from Williams College, a Master’s degree in Business Administration (MBA) and a Master’s degree in Accounting from Northeastern University’s Graduate School of Professional Accounting. He is a Certified Public Accountant (CPA).

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and discovery stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact:    
Kathleen Petrozzelli, Corporate Communications, 617-441-1043
Betsy Stevenson, RaymondStevenson Healthcare, 860-984-1424

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3841934.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
2. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
3. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
4. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
5. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
8. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... Diego (PRWEB) , ... December 07, 2016 , ... ... data from its phase I/II dose escalation and expansion clinical trial for its ... in Vienna, Austria. The purpose of the trial was to determine the safety, ...
Breaking Biology Technology:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):